Policy and industry coverage signaled a shift toward institutionalizing most‑favored‑nation (MFN) pricing in U.S. drug policy. BioCentury’s outlook argued that pegging U.S. prices to international benchmarks is moving from exceptional practice to routine, while the White House urged Congress to codify voluntary MFN deals the administration has negotiated with drugmakers. Drugmakers and payors are weighing implications for access, margins and market strategy; several firms had already agreed to voluntary discounts. MFN schemes tie a country’s reimbursement level to the lowest prices available among comparator countries, and advocates say codification would standardize discounts across the market.